You may also like these news :
Bristol-Myers Squibb to Pay More Than $515 Million to Resolve Allegations
On Friday, the U.S. Department of Justice announced a landmark over one-half billion dollar settlement with Bristol-Myers Squibb based, in part, on their marketing of Abilify, a fairly commonly prescribed antipsychotic used in the treatment of schizophrenia and bipolar disorder. It was a settlement a long time in coming, announced originally in December 2006. Not surprisingly, BMS [...]